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Abstract 
Background: Feline calicivirus (FCV) is a common cause of upper respiratory tract disease in cats worldwide. Its 
characteristically high mutation rate leads to escape from the humoral immune response induced by natural infection 
and/or vaccination and consequently vaccines are not always effective against field isolates. Thus, there is a need to 
continuously investigate the ability of FCV vaccine strain‑induced antibodies to neutralize field isolates.
Methods: Seventy‑eight field isolates of FCV isolated during the years 2008–2012 from Swedish cats displaying 
clinical signs of upper respiratory tract disease were examined in this study. The field isolates were tested for cross‑
neutralization using a panel of eight anti‑sera raised in four pairs of cats following infection with four vaccine strains 
(F9, 255, G1 and 431).
Results: The anti‑sera raised against F9 and 255 neutralised 20.5 and 11.5 %, and 47.4 and 64.1 % of field isolates 
tested, respectively. The anti‑sera against the more recently introduced vaccine strains G1 and 431 neutralized 33.3 
and 70.5 % and 69.2 and 89.7 %, respectively. Dual vaccine strains displayed a higher cross‑neutralization.
Conclusions: This study confirms previous observations that more recently introduced vaccine strains induce anti‑
bodies with a higher neutralizing capacity compared to vaccine strains that have been used extensively over a long 
period of time. This study also suggests that dual FCV vaccine strains might neutralize more field isolates compared 
to single vaccine strains. Vaccine strains should ideally be selected based on updated knowledge on the antigenic 
properties of field isolates in the local setting, and there is thus a need for continuously studying the evolution of FCV 
together with the neutralizing capacity of vaccine strain induced antibodies against field isolates at a national and/or 
regional level.
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Background
Feline calicivirus (FCV) is one of the primary causes of 
infectious upper respiratory tract disease in cats, an 
important disease worldwide [1]. In addition to respira-
tory signs, FCV is frequently associated with chronic 
gingivostomatitis, and highly virulent strains have been 
associated with an acute systemic virulent disease with a 
high case fatality rate [2, 3].
Feline calicivirus is a single-stranded RNA-virus of 
positive sense genome with a high genetic and anti-
genic variability [4–6], associated with escape from the 
humoral immune response induced by natural infection 
and/or vaccination.
FCV is distributed world-wide in the cat population 
and is estimated to be the etiological cause of upper 
respiratory tract disease in 10–50  % of cases [1]. The 
prevalence of FCV varies depending on the manage-
ment and number of cats in a household [7]. In multi-cat 
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households, such as breeding catteries, cat shelters and 
cat colonies, FCV is more prevalent [8, 9]. In Sweden, 
18 % of feline clinical samples submitted for virus isola-
tion to the National Veterinary Institute during the year 
2000 tested positive for FCV, while healthy carriers of 
FCV in Swedish catteries were estimated at 2.6 % [10].
Several commercial vaccines consisting of various vac-
cine strains are available, but due to the high mutation 
rate of FCV, vaccines are not always efficacious [11–13]. 
There is therefore a need to investigate and follow the 
ability of vaccine strain induced antibodies to neutral-
ize field isolates of FCV, in order to evaluate and provide 
updated advice on vaccination strategies at local and/or 
regional levels.
In a previous study, the cross-neutralization of FCV 
field strains isolated in the UK by vaccine strain induced 
antibodies was examined [14]. Here, we used a similar 
approach to investigate whether comparable findings 




A panel of 78 field isolates of FCV grown in  vitro was 
selected from samples submitted between October 2008 
and February 2012 to the National Veterinary Institute 
in Sweden. The samples were all collected from cats 
showing clinical signs compatible with FCV infection, 
although the clinical signs were not always stated in the 
referral form (Additional file 1), and FCV diagnosis had 
been confirmed by transmission electron microscopy 
(TEM).
Virus neutralization test
The isolated FCV isolates were expanded following the 
inoculation of 2 × 105 cell/mL of feline embryo A (FEA) 
cells [15] in T25  cm2 flasks (Corning, NY). Cells were 
incubated at 37 °C in an atmosphere of 5 % CO2. Cultures 
were observed for evidence of cytopathic effect (CPE) for 
up to 4  days post-infection. Once CPE became evident, 
culture fluids were harvested, passed through a 0.45 μm 
filter Minisart syringe filter (Sartorius, UK), aliquoted 
and stored at −80 °C prior to titration.
To titrate the virus isolates, fourfold dilutions of the 
viral stocks (starting at a dilution of 1/500) were prepared 
and then incubated (in quadruplicate, per dilution per 
isolate) in 96-well plates (Thermo scientific, NY) with 
2 × 105 cells/mL of FEA cells in a total volume of 200 µl 
at 37  °C for 48  h. As previosuly, the TCID50 was calcu-
lated as the reciprocal of the final dilution where CPE 
was evident in at least 50 % of the wells [14].
Virus isolates were tested for cross-neutralization using 
a panel of eight anti-sera, raised in four pairs of cats 
infected once by the oronasal route with 1  mL of each 
viral inoculum containing 106 TCID50 of FCV strain F9, 
255, G1 or 431 (one pair of cats was infected with each 
strain). Serial dilutions of anti-sera (threefold, starting 
from a 1/5 dilution) were incubated with 100 TCID50 of 
each of the 78 field isolates in quadruplicate in 96-well 
plates in a total volume of 100 µl for 2 h at 37 °C. Next, 
100  µl of FEA cells were added at a density of 2 ×  105 
cells/mL and the plates were incubated for 48 h. The neu-
tralization titre was calculated as the reciprocal of the 
highest serum dilution where cells were free from CPE in 
at least two of four replicate wells.
Results and discussion
Virus neutralization of FCV field isolates
The FCV field isolates were analysed in a neutralization 
test using eight antisera raised against four commer-
cially available FCV vaccine strains (G1, 431, 255 and F9). 
The same panel of paired anti-sera as had been used by 
Addie and co-workers [14] was used in this study, with 
the exception of the anti-sera raised against FCV G1. 
Fifteen of the field isolates were tested in parallel with 
the batch of anti-sera previously used [14] as well as the 
new pair of anti-sera raised against FCV G1, with simi-
lar results (Additional file 2). This comparison validated 
the use of the new batch of anti-sera, which was subse-
quently used to test all field isolates in this study. The 
paired anti-sera raised against vaccine strains 255 and 
F9, which have been used in vaccines for several dec-
ades, neutralized 47.4 and 64.1  % (strain 255) or 20.5 
and 11.5 % (strain F9) of the field isolates with titres ≥5 
(Table  1). The more recently introduced vaccine strains 
G1 and 431 [16] neutralized 33.3 and 70.5 % (strain G1) 
or 69.2 and 89.7 % (strain 431) of the field isolates with 
titres ≥5. In this study, similar differences in neutralizing 
capacity between paired anti-sera were observed, as had 
previously been recorded [14] (Table 1), consistent with 
inter-cat variation in humoral immune responses to FCV 
infection. As shown in Table 1, strain F9 neutralized few 
field isolates at titers greater than 45. Only one field iso-
late (isolated from cat no. 6 displaying upper respiratory 
signs; Additional files 1 and 2) was not neutralized by any 
of the anti-sera, and another field isolate (isolated from 
cat no. 75 with ulcerative stomatitis; Additional files 1 
and 2) was neutralized at a titer of five by only one of the 
anti-sera raised against strain G1 (S2).
These results are in accordance with previous reports 
[11, 14, 17], indicating the poor ability of antibodies 
against FCV vaccine strain F9 to neutralize current field 
isolates. The reduced capacity of field isolate neutraliza-
tion is driven by the high mutation rate of FCV to escape 
the host immune response leading to emergence of 
escape mutants [6, 18], whether the immunity is induced 
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by vaccination and/or natural infection. The likelihood of 
reduced protection increases when a vaccine strain has 
been extensively used for a long period of time. Antibod-
ies raised against the more recently introduced vaccine 
strains (G1 and 431) demonstrated better neutralization 
of field isolates compared to those raised against strain 
F9 (Table 1); however, we observed no marked difference 
between antibodies raised against these strains com-
pared to FCV vaccine strain 255. To our knowledge, vac-
cine strain 255 has not been extensively used in Sweden, 
although it was introduced a few decades ago; thus, it is 
likely that this strain has not contributed to the immune 
pressure driving FCV mutation.
Combining two vaccine strains increases the likelihood 
of neutralization
Currently, the vaccines registered and in use in Sweden 
contain either one single vaccine strain (either 255 or F9) 
or a combination of two vaccine strains (G1 and 431). 
Therefore, we compared the neutralizing capacity of the 
anti-sera raised against these vaccine strains as they are 
presented in current vaccine preparations. Only 10 % of 
the field isolates were neutralized by both paired anti-
sera raised against strain F9, 44  % were neutralized by 
both paired anti-sera raised against strain 255, whereas 
73  % of the field isolates were neutralized by combina-
tions of the anti-sera against strains G1 and 431, where 
at least one of the paired anti-sera always was neutral-
izing (Table  2). These findings indicate that by combin-
ing two vaccine strains, the likelihood of neutralization 
of the field isolates increases. It is of interest to note 
that, by combining strains 431 and 255 in a putative vac-
cine preparation, an even broader neutralizing capacity 
(60/78; 77 %) would have been seen against this panel of 
field isolates (data not shown). This effect could be the 
result of the greater phylogenetic distance in amino acid 
sequence between isolates 431 and 255, compared to iso-
lates 431 and G1 [16].
The combination of two antigenically distant vaccine 
strains has previously been proposed in order to achieve 
higher cross-neutralizing capacity [14]. When we exam-
ined data from a previous study of field isolates from 
the UK, a similar comparison (combining the results 
obtained for antisera raised against two vaccine strains 
available in one of the current vaccine preparations) gave 
comparable results; 72  % of the field isolates were neu-
tralized by antibodies raised against strains G1 or 431, 
whereas antibodies raised against either strain 255 or F9 
neutralized 34 or 15 %, respectively [14]. The use of dual 
vaccine strains has also been shown to be more effec-
tive in the protection against the virulent systemic (VS-) 
FCV strains [19], although the vaccine strains were not 
comparable to those used in the present study. Further-
more, there was no suggestion of VS-FCV strains being 
included among the field isolates used here (Additional 
file 1).
There is an ongoing discussion that FCV isolated from 
cats displaying clinical signs of chronic FCV infection 
are more often vaccine resistant [20, 21], and thus not 
as often neutralized by anti-sera raised against vaccine 
Table 1 Results of virus neutralization tests
Antisera raised against four feline calicivirus vaccine strains (G1, 431, 255 and F9) were used in the neutralization tests of 78 Swedish field isolates. The number of field 
isolates neutralized by respective antiserum is indicated, with the proportion of neutralized strains shown as a percentage within parenthesis
Titres S1; G1 S2; G1 S3; 431 S4; 431 S5; 255 S6; 255 S7; F9 S8; F9
<5 52 (67) 35 (45) 24 (31) 8 (10) 41 (53) 28 (36) 62 (79) 69 (88)
5–15 20 (26) 22 (28) 39 (50) 32 (41) 28 (36) 19 (24) 12 (15) 7 (9)
45–1215 6 (8) 21 (27) 15 (19) 38 (49) 9 (12) 31 (40) 4 (5) 2 (3)
Table 2 Virus neutralization tests interpreted by combining data from antisera raised against vaccine strains as currently 
presented in registered vaccine preparations
Feline calicivirus (FCV) vaccines registered and used in Sweden either contain F9 or 255 only, or a combination of G1 and 431 vaccine strains. The cutoff for a positive 
neutralizing titer was set to ≥5. The result “possibly negative” indicates that one of the paired neutralizing sera was negative, while the other gave a positive (≥ 5) 
neutralization titer













G1 always pos. 
and 431 neg.  






Always neg. Possibly neg. Always pos. Always neg. Possibly neg. Always pos.
2 19 34 4 19 25 19 34 61 9 8
3 % 24 % 44 % 5 % 24 % 32 % 24 % 44 % 78 % 12 % 10 %
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strains. Since this study was designed to investigate the 
capacity of different vaccine strains to neutralize field 
isolates from Swedish cats, it is not possible to draw any 
conclusions about the relation between clinical signs 
and virus neutralization based on the clinical informa-
tion stated by the veterinary clinicians at submission of 
samples.
Conclusions
This study confirms previous observations that antibod-
ies raised against more recently introduced vaccine FCV 
strains, or vaccine strains used less widely, cross neutral-
ize a higher proportion of circulating field isolates than 
antibodies raised against strains that have been used in 
vaccines extensively for a long time. Moreover, we dem-
onstrated higher cross-neutralization of field isolates 
when considering neutralization data for all of the anti-
sera raised against two strains included in a dual FCV 
vaccine, compared to the neutralization observed by 
the antisera raised against single vaccine strains. Vac-
cine strains should ideally be selected based on updated 
knowledge on the antigenic properties of field isolates in 
the local setting, and there is thus a need to continuously 
study the evolution of FCV and the neutralizing capacity 
of vaccine strain-induced antibodies against field isolates 
at a national and/or regional level.
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